About Us
The RenalPro System stands out for its simple, elegant technology: ideal for kidney preservation and AKI prevention.
Our mission is to help improve morbidity and mortality rates, preserve quality of life, and reduce healthcare costs with our proprietary, IP-rich innovations currently protected by 22 patents and patent pending applications.
Management Team
Decade of experience guiding strategic product and business development. Managing Partner at Imagine Bio, a strategic consultancy that supported innovation strategy at clients such as JNJ and Boehringer Ingelheim. Former CEO at NeuroQuest. Studied finance and biochemistry at Miami Univ. of Ohio.
Ilya Budik
CEO
Ethan Benovitz is a seasoned investor with more than 25 years of experience investing in the healthcare and technology sectors. He began his career as a corporate attorney after earning his JD from Harvard Law School. Ethan’s expertise in strategy, corporate finance and governance make him a trusted advisor to a variety of corporations and executives.
Ethan Benovitz, JD
Chairman
18 years of experience managing clinical and regulatory affairs at emerging medtech companies, including dozens of clinical trials as well as FDA, CE, and Japanese approvals at Nucleix, Oridian (acq. by Medtronic), and Brainsway (NASDAQ: BWAY).
Shmulik Adler
SVP Clinical & Regulatory AffairsLaura Dern
President
Cardiothoracic surgeon with 25+ years of clinical experience in UK and UAE. Involved in clinical validation of three emerging medical technologies including RenalGuard’s UK validation study in CSA-AKI. Author of 137 peer-reviewed publications.
Heyman Luckraz, FRCS, MD
VP Medical Affairs
Cardiothoracic surgeon with 25+ years of clinical experience in UK and UAE. Involved in clinical validation of three emerging medical technologies including RenalGuard’s UK validation study in CSA-AKI. Author of 137 peer-reviewed publications.
William “Pepper” Denman, MD
Sr. Medical & Industry Advisor
Partner at Hogan Lovells. Extensively recognized as leading regulatory advisor with over 25 years of experience guiding dozens of innovative devices through successful FDA approvals. BS mechanical engineering at MIT, JD Georgetown.
Janice Hogan, JD
Sr. Regulatory Advisor
40+ years of experience in medical device sales in US, EMEA, and APAC regions. Led Acist sales launch through growth and post-acquisition to Bracco. Track record of international expansion, distribution management, and channel marketing.
Robin Luper,
SVP Sales, InternationalScientific Advisory Board
Prof. of Nephrology at Univ. of Vermont. Leading KOL in field of AKI and principal investigator for numerous important trials. Member of the NIH consortium for AKI biomarkers.
Richard Solomon, MD
Nephrologist, University of Vermont
Assc. Professor of Medicine at Harvard Medical School. Director of Clinical & Translational Research in AKI at Brigham & Women’s Hospital. Recognized KOL with extensive clinical publications on CSA-AKI related research.
David Leaf, MD
Nephrologist, Harvard Medical School
Chairman, Dept. of Intensive Care at Cleveland Clinic. 25+ years of experience in cardiac anesthesia and critical care in US, UK, & Canada. KOL with extensive publications including recent clinical guidelines for reduction of CSA-AKI.
Andrew Shaw, MD
Intensive Care & Anesthesiologist, Cleveland Clinic
Cardiothoracic Surgeon and Medical Director of Heart, Vascular and Critical Care Unit at Baystate Medical Center. Head of ERAS (Enhanced Recovery After Surgery) Society.
Dan Engelman, MD
Cardiothoracic Surgeon, Head of ERAS Society
Chair, Department of Surgery at Baylor College of Medicine and Texas Heart Institute. KOL with extensive clinical research and publications in Cardiac Surgery and CSA-AKI.
Todd Rosengart, MD, FACS
Cardiothoracic Surgeon, Baylor College of Medicine
Leading KOL in CSA-AKI and principal investigator for numerous important trials. Member of Enhanced Recovery After Surgery (ERAS) society.
Prof. Alex Zarbock, MD
Anesthesiologist, University Hospital MünsterOur Investors
